MYC and prostate cancer: We observed for the first time that inhibition of 5-Lox by shRNA or by chemical inhibitor, MK591, strongly downregulates the mRNA and protein levels as well as transcriptional activity of c-Myc in the enzalutamide-resistant prostate cancer cells (Fig. 2).